Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer

Oncogene

Volumn 29, Issue 39, 2010, Pages 5359-5369

  Sakamoto, K ^a   Triplett, A A ^a   Schuler, L A ^b   Wagner, K U ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Breast cancer; Gene targeting; Janus kinase 2; Prolactin; Stat5; Transgenic

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; JANUS KINASE 2; PROLACTIN; STAT5 PROTEIN; PROLACTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER GROWTH; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; UPREGULATION; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; NUDE MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; JANUS KINASE 2; MICE; MICE, KNOCKOUT; MICE, NUDE; MICE, TRANSGENIC; PROLACTIN; RECEPTORS, PROLACTIN; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

MUS MUSCULUS;

EID: 77957586805     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.274     Document Type: Article

References (52)

1. Aoui-Jamali MA, Song DJ, Benlimame N, Yen L, Deng X, Hernandez-Perez M et al. (2003). Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. Cancer Res 63: 3764-3774.
2. Arendt LM, Rose-Hellekant TA, Sandgren EP, Schuler LA. (2006). Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice. Am J Pathol 168: 1365-1374.
3. Arendt LM, Schuler LA. (2008). Prolactin drives estrogen receptoralpha- dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males. Am J Pathol 172: 194-202.
4. Boulanger CA, Wagner KU, Smith GH. (2005). Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression. Oncogene 24: 552-560.
5. Brockman JL, Schroeder MD, Schuler LA. (2002). PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol 16: 774-784.
6. Brockman JL, Schuler LA. (2005). Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter. Mol Cell Endocrinol 239: 45-53.
7. Cardiff RD. (1998). Are the TDLU of the human the same as the LA of mice? J Mammary Gland Biol Neoplasia 3: 3-5.
8. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. (1995). Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/ paracrine loop. Am J Pathol 146: 695-705.
9. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. (2004). Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108: 665-671.
10. Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX et al. (2004). Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 24: 8037-8047.
11. Diehl JA, Cheng M, Roussel MF, Sherr CJ. (1998). Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511.
12. Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, Gonzalez L, Porque PG, Leon J et al. (2004). Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene 23: 7378-7390.
13. Garcia-Martinez JM, Calcabrini A, Gonzalez L, Martin-Forero E, gullo-OrtunoMT, Simon V et al. (2010). A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling. Cell Signal 22: 415-426.
14. Ginsburg E, Vonderhaar BK. (1995). Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 55: 2591-2595.
15. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C et al. (1999). Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91: 629-634. (Pubitemid 29194050)
16. Henry MD, Triplett AA, Oh KB, Smith GH, Wagner KU. (2004). Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice. Oncogene 23: 6980-6985.
17. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100: 8933-8938.
18. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ et al. (1997). Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 16: 6926-6935.
19. Humphreys RC, Hennighausen L. (1999). Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 10: 685-694.
20. Iavnilovitch E, Cardiff RD, Groner B, Barash I. (2004). Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 112: 607-619.
21. Iavnilovitch E, Groner B, Barash I. (2002). Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 1: 32-47.
22. Kim A, Liu B, Ordonez-Ercan D, Alvarez K, Jones L, McKimmey C et al. (2005). Functional interaction between mouse erbB3 and wildtype rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res 7: R708-R718.
23. Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, Wagner KU. (2004). Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis 40: 52-57.
24. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907-913.
25. Matulka LA, Triplett AA, Wagner KU. (2007). Parity-induced mammary epithelial cells are multipotent and express cell surface markers associated with stem cells. Dev Biol 303: 29-44.
26. Matulka LA, Wagner KU. (2005). Models of Breast Cancer. Drug Discov Today Dis Models 2: 1-6.
27. Medina D, Kittrell FS. (2000). Establishment of mouse mammary cell lines. In: Ip MM, Ash BB (eds). Methods in Mammary Gland Biology and Breast Cancer, chapter 13. Kluwer Academic/Plenum Publishers: New York. pp 137-145.
28. Miermont AM, Parrish AR, Furth PA. (2010). Role of ERa in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis. Carcinogenesis 31: 1124-1131.
29. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J et al. (2004). Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22: 2053-2060.
30. Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE et al. (2007). Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 26: 543-553.
31. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H et al. (1997). Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 11: 167-178.
32. Pardanani A. (2007). JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22: 23-30.
33. Ren S, Cai HR, Li M, Furth PA. (2002). Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21: 4335-4339.
34. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. (2003). Prolactin induces ERalphapositive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 22: 4664-4674.
35. Sakamoto K, Creamer BA, Triplett AA, Wagner KU. (2007). The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells. Mol Endocrinol 21: 1877-1892.
36. Sakamoto K, Lin WC, Triplett AA, Wagner KU. (2009). Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy. Cancer Res 69: 6642-6650.
37. Shillingford JM, Miyoshi K, Robinson GW, Grimm SL, Rosen JM, Neubauer H et al. (2002). Jak2 is an essential tyrosine kinase involved in pregnancy-mediated development of mammary secretory epithelium. Mol Endocrinol 16: 563-570.
38. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
39. Tang JZ, Zuo ZH, Kong XJ, Steiner M, Yin Z, Perry JK et al. (2010). Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology 151: 43-55.
40. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D et al. (1998). Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93: 841-850.
41. Tornell J, Rymo L, Isaksson OG. (1991). Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice. Int J Cancer 49: 114-117.
42. Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A et al. (2010). Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res 70: 1711-1721.
43. Triplett AA, Montagna C, Wagner KU. (2008). A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1- associated mammary tumorigenesis. Neoplasia 10: 1325-1334.
44. Tworoger SS, Hankinson SE. (2006). Prolactin and breast cancer risk. Cancer Lett 243: 160-169.
45. Wagner KU, Boulanger CA, Henry MD, Sgagias M, Hennighausen L, Smith GH. (2002). An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development 129: 1377-1386.
46. Wagner KU, Krempler A, Triplett AA, Qi Y, George NM, Zhu J et al. (2004). Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol 24: 5510-5520.
47. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R, Hennighausen L. (2001). Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 10: 545-553.
48. Wagner KU, Rui H. (2008). Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 13: 93-103.
49. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L et al. (1997a). Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 25: 4323-4330.
50. Wagner KU, Young III WS, Liu X, Ginns EI, Li M, Furth PA et al. (1997b). Oxytocin and milk removal are required for post-partum mammary-gland development. Genes Funct 1: 233-244.
51. Wellings SR, Jensen HM, Marcum RG. (1975). An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 55: 231-273.
52. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. (1997). Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 100: 2744-2751.